European Commission (EC) New medicines authorised – Breyanzi (Cell and Gene Therapy Catapult – Regulatory Round-up – May 2022)
Breyanzi (lisocabtagene maraleucel) received a marketing authorisation valid throughout the EU on 4 April 2022. It was developed for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.
See all of Catapult’s Regulatory Round-up for May 2022 here.
Published on the 6th of June 2022.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (3 août 2022). European Commission (EC) New medicines authorised – Breyanzi (Cell and Gene Therapy Catapult – Regulatory Round-up – May 2022). ELSIBI. Consulté le 19 février 2026 à l’adresse https://doi.org/10.58079/o61j





